Author

D. A. Oyarzun

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:machine learning (classical)· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

A. Quintanilla· 1 shared B. Wang· 1 shared J. C. Acosta· 1 shared J. C. Dawson· 1 shared J. Fa-arun· 1 shared J. Sun· 1 shared N. Carragher· 1 shared R. Brown· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Quintanilla

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivSep 2, 2022

P1 bacteriophage-enabled delivery of CRISPR-Cas9 antimicrobial activity against Shigella flexneri

Y. W. Huan, V. Torraca, R. Brown…·B. Wang

This study uses a P1 bacteriophage to deliver CRISPR-Cas9 for targeted killing of Shigella flexneri in zebrafish larvae, reducing bacterial load and improving survival.

DOI 10.1021/acssynbio.2c00465

zebrafishCRISPR screen

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 26, 2022

Discovery of new senolytics using machine learning

V. Smer-Barreto, A. Quintanilla, R. J. Elliot…·D. A. Oyarzun

This paper uses machine learning to discover three new senolytic compounds by screening FDA-approved drugs and clinical candidates.

DOI 10.1101/2022.04.26.489505

humanmachine learning (classical)

𝕏 PostBluesky